Table 1 Patient demographics and the relevance to overall survival
Variables | No. of patients | 3-years survival rate (%) | Median survival, month (95% CI) | p value |
|---|---|---|---|---|
Age (yrs) | 0.144 | |||
> 55 | 47 | 53.6 | 42.0 (19.1–64.9) | |
< =55 | 44 | 39.5 | 26.0 (17.2–34.8) | |
Sex | ||||
Male | 88 | 46.3 | 32.0 (21.9–42.1) | 0.799 |
Female | 3 | 66.7 | -a | |
Location | 0.136 | |||
Upper third | 24 | 35.4 | 15.0 (0.0–36.6) | |
Middle third | 45 | 44.2 | 27.0 (13.7–40.3) | |
Lower third | 22 | 64.5 | -a | |
Differentiation | 0.096 | |||
Grade I | 3 | 33.3 | 12.0 (10.4–13.6) | |
Grade II | 42 | 44.1 | 27.0 (12.6–41.4) | |
Grade III | 11 | 37.9 | 11.0 (8.1–13.9) | |
N/A | 35 | 57.0 | -a | |
Tumor size (cm) | 0.665 | |||
< 2.5 | 51 | 39.8 | 27.0 (13.4–40.6) | |
> = 2.5 | 40 | 54.4 | 37.0 (17.3–56.7) | |
cT stage | 0.918 | |||
T1 | 4 | 50.0 | - | |
T2 | 17 | 51.5 | 37.0 (21.0–53.0) | |
T3 | 66 | 45.7 | 27.0 (12.1–41.9) | |
T4 | 4 | 50.0 | -a | |
cN stage | 0.778 | |||
N0 | 27 | 36.5 | 32.0 (22.3–41.7) | |
N1 | 24 | 54.8 | 37.0 (9.06–64.9) | |
N2 | 17 | 41.0 | 21.0 (8.6–33.4) | |
N3 | 13 | 27.2 | 24.0 (17.4–30.6) | |
ypT stage | 0.908 | |||
T0 | 32 | 53.4 | 37.0 (14.6–59.4) | |
Tis/1 | 11 | 42.4 | 25.0 (6.3–43.7) | |
T2 | 18 | 54.0 | 37.0 (15.5–58.5) | |
T3 | 24 | 34.1 | 27.0 (14.0–40.0) | |
T4 | 6 | 44.4 | 14.0 (2.2–25.8) | |
ypN stage | 0.032 † | |||
N0 | 56 | 53.5 | 37.0 (21.3–52.7) | |
N1 | 20 | 50.4 | 37.0 (2.0–72.0) | |
N2 | 12 | 13.0 | 15.0 (12.0–18.0) | |
N3 | 3 | 33.0 | 24.0 (0.0–49.6) | |
ypM stage | 0.019 † | |||
M0 | 86 | 49.1 | 35.0 (23.8–46.2) | |
M1 | 5 | 0.0 | 13.0 (0.1–25.9) | |
ypStage | 0.031 † | |||
0 | 25 | 63.8 | -a | |
I | 7 | 42.9 | 25.0 (0.0–58.4) | |
II | 30 | 52.2 | 37.0 (20.5–53.5) | |
III | 24 | 34.9 | 16.0 (7.5–24.5) | |
IV | 5 | 0.0 | 13.0 (0.1–25.9) | |
TRG | 0.454 | |||
0 | 29 | 57.9 | 37.0 | |
1 | 32 | 48.2 | 25.0 (5.8–44.3) | |
2 | 15 | 17.6 | 27.0 (12.4–41.6) | |
3 | 15 | 45.0 | 26.0 (3.6–48.4) | |
LVI | 0.024 † | |||
No | 70 | 55.0 | 37.0 (26.3–47.7) | |
Yes | 21 | 23.4 | 14.0 (8.9–19.1) | |
PNI | 0.014 † | |||
No | 76 | 55.2 | 37.0 (26.1–47.9) | |
Yes | 15 | 15.6 | 13.0 (9.4–16.6) | |
ECI | 0.002 † | |||
No | 77 | 50.5 | 37.0 (23.9–50.1) | |
Yes | 14 | 23.9 | 11.0 (7.9–14.1) | |
Total resected lymph node number | 0.134 | |||
< 18 | 44 | 55.8 | 37.0 (21.4–52.6) | |
> =18 | 47 | 38.2 | 23.0 (10.6–35.4) | |
Incomplete resection | 0.033 † | |||
No | 63 | 55.0 | 37.0 (26.1–47.9) | |
Yes | 28 | 26.0 | 21.0 (9.5–32.5) | |
Surgical approach | 0.950 | |||
MIE | 62 | 47.9 | 35.0 (22.0–48.0) | |
Hybrid | 29 | 30.7 | 27.0 (15.0–39.0) | |
Adjuvant therapy | 0.434 | |||
No | 67 | 47.4 | 32.0 (18.9–45.1) | |
Yes | 24 | 42.4 | 35.0 (19.2–50.8) | |